Value of accelerated hyperfraction dozes of radiation in primary radiation treatment for Hodgkin’s lymphoma
Methods: Were examined 145 patients with Hodgkin’s lymphoma (HL) II-IIIAB who received AHF within 1985-1997. A comparison was carried out with the comparable group of 110 patients given CF. The AHF schedule was carried out by admission of the single dose 1,35 Gy twice a day with interval 3,54 hs to...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-11-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/674 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849241191066894336 |
|---|---|
| author | N. V. Ilyin J. N. Vinogradova E. N. Nikolaeva E. V. Smirnova |
| author_facet | N. V. Ilyin J. N. Vinogradova E. N. Nikolaeva E. V. Smirnova |
| author_sort | N. V. Ilyin |
| collection | DOAJ |
| description | Methods: Were examined 145 patients with Hodgkin’s lymphoma (HL) II-IIIAB who received AHF within 1985-1997. A comparison was carried out with the comparable group of 110 patients given CF. The AHF schedule was carried out by admission of the single dose 1,35 Gy twice a day with interval 3,54 hs to basic registration points (bifurcation of trachea and paraaortal lymphatic nodes). The total doses in clinically involved nodes were approximately 40 Gy; zones of subclinical involvement — 36 Gy.Results: Objective response was obtained 87,4% in the AHF group and 90,0% in the CF group. Median follow-up was 144 months: AHF - 144 months, CF — 150 months. Quantity of recurrences was significantly higher in patients with CF than in those with AHF — 28,3% and 16,5% (p=0,02), respectively. 10-years overall survival was 82,8% in AHF group and 72,1% in the CF group. 10-year recurrence-free survival was 81,5% in the AHF group and 69,8% in the CF group (p=0,04). Analysis of clinical date showed essential reduction of radiation pneumonitis rate at AHF in comparison with CF: 13,1% vs. 25,4% (p=0,01), postradiation pericarditis: 2,1% vs. 7,3% (p=0,04), leucopenia grade IV: 4,1% vs. 12,7%.Conclusions: Clinical analysis revealed the benefits of single dose decrease from 2 Gy to 1,35 Gy at the twice a day irradiation scheme. The AHF is an effective schedule of RT and promotes to the recurrence frequency reduction, increases recurrence-free survival, decreases of the cardiopulmonary complication risk and leucopenia rate. |
| format | Article |
| id | doaj-art-b97f72299f54455d98cd4d9d7a25a3ad |
| institution | Kabale University |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2022-11-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-b97f72299f54455d98cd4d9d7a25a3ad2025-08-20T04:00:14ZrusABV-pressОнкогематология1818-83462413-40232022-11-0104475210.17650/1818-8346-2007-0-4-47-52552Value of accelerated hyperfraction dozes of radiation in primary radiation treatment for Hodgkin’s lymphomaN. V. Ilyin0J. N. Vinogradova1E. N. Nikolaeva2E. V. Smirnova3Central Research Istitute for RadiologyCentral Research Istitute for RadiologyCentral Research Istitute for RadiologyCentral Research Istitute for RadiologyMethods: Were examined 145 patients with Hodgkin’s lymphoma (HL) II-IIIAB who received AHF within 1985-1997. A comparison was carried out with the comparable group of 110 patients given CF. The AHF schedule was carried out by admission of the single dose 1,35 Gy twice a day with interval 3,54 hs to basic registration points (bifurcation of trachea and paraaortal lymphatic nodes). The total doses in clinically involved nodes were approximately 40 Gy; zones of subclinical involvement — 36 Gy.Results: Objective response was obtained 87,4% in the AHF group and 90,0% in the CF group. Median follow-up was 144 months: AHF - 144 months, CF — 150 months. Quantity of recurrences was significantly higher in patients with CF than in those with AHF — 28,3% and 16,5% (p=0,02), respectively. 10-years overall survival was 82,8% in AHF group and 72,1% in the CF group. 10-year recurrence-free survival was 81,5% in the AHF group and 69,8% in the CF group (p=0,04). Analysis of clinical date showed essential reduction of radiation pneumonitis rate at AHF in comparison with CF: 13,1% vs. 25,4% (p=0,01), postradiation pericarditis: 2,1% vs. 7,3% (p=0,04), leucopenia grade IV: 4,1% vs. 12,7%.Conclusions: Clinical analysis revealed the benefits of single dose decrease from 2 Gy to 1,35 Gy at the twice a day irradiation scheme. The AHF is an effective schedule of RT and promotes to the recurrence frequency reduction, increases recurrence-free survival, decreases of the cardiopulmonary complication risk and leucopenia rate.https://oncohematology.abvpress.ru/ongm/article/view/674hodgkin’s diseasehodgkin’s lymphomaradiation therapyaccelerated hyperfraction |
| spellingShingle | N. V. Ilyin J. N. Vinogradova E. N. Nikolaeva E. V. Smirnova Value of accelerated hyperfraction dozes of radiation in primary radiation treatment for Hodgkin’s lymphoma Онкогематология hodgkin’s disease hodgkin’s lymphoma radiation therapy accelerated hyperfraction |
| title | Value of accelerated hyperfraction dozes of radiation in primary radiation treatment for Hodgkin’s lymphoma |
| title_full | Value of accelerated hyperfraction dozes of radiation in primary radiation treatment for Hodgkin’s lymphoma |
| title_fullStr | Value of accelerated hyperfraction dozes of radiation in primary radiation treatment for Hodgkin’s lymphoma |
| title_full_unstemmed | Value of accelerated hyperfraction dozes of radiation in primary radiation treatment for Hodgkin’s lymphoma |
| title_short | Value of accelerated hyperfraction dozes of radiation in primary radiation treatment for Hodgkin’s lymphoma |
| title_sort | value of accelerated hyperfraction dozes of radiation in primary radiation treatment for hodgkin s lymphoma |
| topic | hodgkin’s disease hodgkin’s lymphoma radiation therapy accelerated hyperfraction |
| url | https://oncohematology.abvpress.ru/ongm/article/view/674 |
| work_keys_str_mv | AT nvilyin valueofacceleratedhyperfractiondozesofradiationinprimaryradiationtreatmentforhodgkinslymphoma AT jnvinogradova valueofacceleratedhyperfractiondozesofradiationinprimaryradiationtreatmentforhodgkinslymphoma AT ennikolaeva valueofacceleratedhyperfractiondozesofradiationinprimaryradiationtreatmentforhodgkinslymphoma AT evsmirnova valueofacceleratedhyperfractiondozesofradiationinprimaryradiationtreatmentforhodgkinslymphoma |